|
Andy, In an article entitled " The Biotechnology Outlook for 1998", they thought that ALKS, CORR, ALTN,& GILD "will emerge as our top " b/t investment ops in '98. Later on in the article, in a section entitled " Down & out stocks that could recover in '98 include..,LGND." Only 4 sentences on us. An important one in addition to what was previously mentioned, was an expectation that results are expected from the P2/3 trial of oral Targretin in CTCL in 1H:98 & from P2 trials in it to treat KS, ovarian, & prostate cancer in early '98. There's no more , no less. Bernie. P.S. I got a look at the corporate profile put out by RESEARCH Inc. & sent to every stock broker they can find. They listed dates for first possible revenue. Panretin gel '98; Panretin oral '99; Targrtin Gel '99; Targretin Oral '99; LGD1550 '02; Droloxifene '99; CP 336,156{PFE} '03. Interesting words included"...retinoids may prove to be safer than currently available chemotherapy, which can be toxic to healthy & diseased cells alike." This sentence seems to imply that LGND sees its cancer competition as chemotherapy. "Encouraging results have been reported using both Targretin Gel & Oral Capsules to treat patients with CTCL." { Since this report is most likely written by Lgnd or at worst principally written by them, this is encouraging that the reported results will be satisfactory}".LGND scientists are also working to discover small molecule drugs that mimic leptin." Highlighted in specialized print under a title " Osteoporosis & Hormone Replacement Therapy" was" Ligand's scientists & collaborators have discovered ways to block & mimic the 2 separate activational domains of the estrogen receptor, the progesterone receptor & the androgen receptor. These insights may result in fewer side effects in new drugs for osteoporosis, male & female hormone replacement therapy, breast cancer & prostate cancer." "LGND's in-depth understanding of the multiple roles hormones play in women's & men's health has provided multiple opportunities to develop drugs & to form drug development alliances". "LGND is continuing its internal programs to develop potential androgen therapies for men & women" " A pre-clinical compound to lower low density lipoprotein {LDL} cholesterol levels has been identified with Glaxo & could enter the clinic in '98." { We thought it "would"}. A glucocorticid receptor based product is in preclinical development & LGND expects that ABT could have the drug in the clinic in '98." How the heck are they going to put 7 compounds in the clinic in '98 with all these "coulds" instead of "woulds'? " LGND's core technologies, combined with a strong intellectual property position, are well-suited to take advantage of the new information & molecular targets being uncovered". " LGND's scientists are enhancing that approach by identifying specific molecular " sub targets" within the receptor complex which act through pathways that may permit the discovery of even more refined molecules ,representing a new generation of drugs." Bernie. |
